Compare NVX & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVX | ANIX |
|---|---|---|
| Founded | 2012 | 1982 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.9M | 114.0M |
| IPO Year | 2021 | 2013 |
| Metric | NVX | ANIX |
|---|---|---|
| Price | $2.95 | $3.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 176.5K | ★ 242.1K |
| Earning Date | 04-30-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | $3,904.19 | N/A |
| Revenue Next Year | $91.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $2.32 |
| 52 Week High | $4.60 | $5.46 |
| Indicator | NVX | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 77.27 | 36.65 |
| Support Level | $0.67 | $2.77 |
| Resistance Level | $4.60 | $3.09 |
| Average True Range (ATR) | 0.18 | 0.24 |
| MACD | 0.26 | -0.06 |
| Stochastic Oscillator | 59.65 | 4.67 |
NOVONIX Ltd is a battery technology company developing and scaling materials and equipment critical to the lithium-ion battery supply chain. The company has three operating segments: Battery Materials: It develops and manufactures battery anode materials, ii) Battery Technology: It develops and manufactures battery cell testing equipment, performs consulting services and carries out research and development in battery development, and Graphite Exploration: It manages the maintenance and future development of Mount Dromedary natural graphite deposit. The majority of the company's revenue is derived from the Battery Technology segment. Geographically, the maximum revenue is derived from North America, followed by Asia, and Europe.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.